

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Hasnain Faheem</u> (Last) (First) (Middle) 14 CAMBRIDGE CENTER (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIOGEN IDEC INC. [BIIB]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Oncology/Rheumatology SBU</u>
	3. Date of Earliest Transaction (Month/Day/Year) 04/08/2008	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$63.71	38,441.2214 ⁽²⁾	D	
Common Stock	04/08/2008		S ⁽¹⁾		200	D	\$63.79	38,241.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		200	D	\$63.89	38,041.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$63.93	37,941.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		300	D	\$64.18	37,641.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		500	D	\$64.32	37,141.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		400	D	\$64.38	36,741.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		2	D	\$64.39	36,739.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		200	D	\$64.4	36,539.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		998	D	\$64.42	35,541.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		800	D	\$64.44	34,741.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		25	D	\$64.48	34,716.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		300	D	\$64.51	34,416.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.54	34,316.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.58	34,216.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.61	34,116.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		300	D	\$64.63	33,816.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.64	33,716.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.67	33,616.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		300	D	\$64.72	33,316.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		400	D	\$64.79	32,916.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		400	D	\$64.82	32,516.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.92	32,416.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		200	D	\$64.93	32,216.2214	D	
Common Stock	04/08/2008		S ⁽¹⁾		100	D	\$64.94	32,116.2214	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (e.g., puts, calls, warrants, options, convertible securities) (Month/Day/Year)	5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
<p>Remarks:</p> <p>1. Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.</p> <p>2. Includes 464,597.8 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 3/31/2008.</p> <p>Code V (A) (D) Date Exercisable Expiration Date Signature of Reporting Person Title Shares Date</p> <p style="text-align: right;">Robert A. Licht, Attorney in Fact for Faheem Hasnain 04/10/2008</p>										

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.